LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state
暂无分享,去创建一个
Ron Rotkopf | Randy L. Johnson | M. Oren | Anat Gershoni | V. Gorgoulis | D. Leshkowitz | E. Ainbinder | Y. Aylon | N. Furth | I. Pateras | I. Schmitt | Vassiliki Vlachou | Irina Rivkin | D. Bakaev | Yael Aylon
[1] I. Ellis,et al. The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. , 2017, The American journal of pathology.
[2] Y. Aylon,et al. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway , 2017, Cell Death and Differentiation.
[3] G. Wahl,et al. Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity , 2017, npj Breast Cancer.
[4] E. Polley,et al. Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer , 2017, Theranostics.
[5] Zhengdong D. Zhang,et al. Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model , 2017, BMC Genomics.
[6] Michael B. Stadler,et al. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα , 2017, Nature.
[7] Matthew V. Holt,et al. The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity , 2016, Cell.
[8] V. Rotter,et al. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. , 2016, Cold Spring Harbor perspectives in medicine.
[9] B. Gumbiner,et al. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis , 2016, Mammalian Genome.
[10] Zhi-hua Li,et al. Luminal B breast cancer: patterns of recurrence and clinical outcome , 2016, Oncotarget.
[11] Jeong-Hwan Kim,et al. LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development , 2016, Nature Communications.
[12] S. Friedman,et al. The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation , 2016, Genes & development.
[13] Doron Lancet,et al. GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data , 2016, Omics : a journal of integrative biology.
[14] Ron Rotkopf,et al. RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer , 2016, Cell reports.
[15] S. Bicciato,et al. YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins , 2016, EMBO reports.
[16] M. Jackson,et al. Cancer Stem Cell Plasticity Drives Therapeutic Resistance , 2016, Cancers.
[17] Gwendolyn M. Jang,et al. Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. , 2015, Cell host & microbe.
[18] S. Kucucuk,et al. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer , 2015, Medicine.
[19] E. Domany,et al. Down-regulation of LATS kinases alters p53 to promote cell migration , 2015, Genes & development.
[20] G. Halder,et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway , 2015, Nature Communications.
[21] Alexander Dobin,et al. Mapping RNA‐seq Reads with STAR , 2015, Current protocols in bioinformatics.
[22] Ying Zhou,et al. Expression of LATS family proteins in ovarian tumors and its significance. , 2015, Human pathology.
[23] Kun-Liang Guan,et al. The emerging roles of YAP and TAZ in cancer , 2015, Nature Reviews Cancer.
[24] M. Lazar,et al. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.
[25] E. Iversen,et al. A joint analysis of metabolomics and genetics of breast cancer , 2014, Breast Cancer Research.
[26] Souhad El Akoum,et al. PPAR Gamma at the Crossroads of Health and Disease: A Masterchef in Metabolic Homeostasis , 2014 .
[27] Karen H. Vousden,et al. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.
[28] Andrew J Ewald,et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis , 2014, Genes & development.
[29] Andrew J. Ewald,et al. Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program , 2013, Cell.
[30] Xiaoxiang Hu,et al. Lats2 Modulates Adipocyte Proliferation and Differentiation via Hippo Signaling , 2013, PloS one.
[31] N. Inestrosa,et al. Peroxisome Proliferator-Activated Receptor (PPAR) γ and PPARα Agonists Modulate Mitochondrial Fusion-Fission Dynamics: Relevance to Reactive Oxygen Species (ROS)-Related Neurodegenerative Disorders? , 2013, PloS one.
[32] Kishore R. Sakharkar,et al. Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology , 2013, Journal of drug targeting.
[33] Shelley M Enger,et al. Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[34] R. Cardiff,et al. Proliferative and Nonproliferative Lesions of the Rat and Mouse Mammary, Zymbal’s, Preputial, and Clitoral Glands , 2012, Toxicologic pathology.
[35] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[36] Leandro Martínez,et al. Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists , 2012, PloS one.
[37] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[38] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[39] Byung-Chul Oh,et al. Mammalian Ste20-Like Kinase and SAV1 Promote 3T3-L1 Adipocyte Differentiation by Activation of PPARγ , 2012, PloS one.
[40] Ben Tran,et al. Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.
[41] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[42] Valerie Speirs,et al. Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.
[43] I. Ellis,et al. Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation? , 2011, The Journal of pathology.
[44] Nicola Elvassore,et al. Role of YAP/TAZ in mechanotransduction , 2011, Nature.
[45] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[46] M. Oren,et al. The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. , 2010, Genes & development.
[47] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[48] A. Ashworth,et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. , 2010, Cell stem cell.
[49] H. Brauch,et al. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation , 2010, Proceedings of the National Academy of Sciences.
[50] Wei Zhang,et al. PPARgamma activation induces autophagy in breast cancer cells. , 2009, The international journal of biochemistry & cell biology.
[51] S. Fox,et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Network Boston.
[52] H. Aburatani,et al. The Peroxisome Proliferator-Activated Receptor γ/Retinoid X Receptor α Heterodimer Targets the Histone Modification Enzyme PR-Set7/Setd8 Gene and Regulates Adipogenesis through a Positive Feedback Loop , 2009, Molecular and Cellular Biology.
[53] Janet Rossant,et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. , 2009, Developmental cell.
[54] Jiang Shou,et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.
[55] Jianmin Zhang,et al. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. , 2008, Cancer research.
[56] R. Schiff,et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.
[57] P. Neven,et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[59] M. Oren,et al. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. , 2006, Genes & development.
[60] David Basiji,et al. Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow. , 2006, Journal of immunological methods.
[61] J. Mesirov,et al. From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .
[62] C. Caldas,et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Esteban O. Mazzoni,et al. The Growth Regulators warts/lats and melted Interact in a Bistable Loop to Specify Opposite Fates in Drosophila R8 Photoreceptors , 2005, Cell.
[64] Thomas Benjamin,et al. TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell Differentiation , 2005, Science.
[65] Martin Fenner,et al. Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer , 2005 .
[66] Y. Miyoshi,et al. Down-Regulation of LATS1 and LATS2 mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers , 2005, Clinical Cancer Research.
[67] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[68] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[69] Sander Kersten,et al. Roles of PPARs in health and disease , 2000, Nature.
[70] E. Williamson,et al. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. , 2000, Journal of the National Cancer Institute.
[71] R. Cardiff,et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.
[72] M. Sporn,et al. A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .
[73] B. Spiegelman,et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[74] W. Tao,et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction , 1999, Nature Genetics.
[75] B. Spiegelman,et al. Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.
[76] J Isola,et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] J. Lehmann,et al. The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .
[78] G. Giamas,et al. LATS2 is a modulator of estrogen receptor alpha. , 2013, Anticancer research.
[79] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[80] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[81] P. Neven,et al. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .
[82] S. Konduri,et al. Estrogen Receptor- (cid:1) Binds p53 Tumor Suppressor Protein Directly and Represses Its Function , 2006 .
[83] C. Osborne,et al. Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.
[84] J. Pollard,et al. Animal Model Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases , 2003 .
[85] R. Cardiff,et al. Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .